Quick Answer
Contineum Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2024.
Contineum Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | — | $0.00 -100.0% |
$50.00M | — |
| Revenue (ASC 606) | — | $0.00 -100.0% |
$50.00M | — |
| Net Income | -$59.98M -41.9% |
-$42.26M -286.0% |
$22.72M | — |
| Diluted EPS | -$2.17 +0.5% |
-$2.18 -2825.0% |
$0.08 | — |
| Total Assets | $276.64M +30.0% |
$212.85M +63.2% |
$130.39M | — |
| Cash and Equivalents | $75.60M +244.5% |
$21.94M +41.3% |
$15.53M | — |
| Stockholders Equity | $260.99M +31.8% |
$198.07M +391.5% |
-$67.94M +27.1% |
-$93.21M |
| R&D Expense | $51.52M +34.1% |
$38.42M +39.2% |
$27.60M | — |
| Operating Income | -$68.06M -33.7% |
-$50.89M -416.6% |
$16.08M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$12.79M | -24.6% | +20.2% |
| Diluted EPS | September 30, 2024 | -$0.40 | +85.1% | -2.6% |
| Total Assets | September 30, 2025 | $190.85M | -11.7% | +4.4% |
| Cash and Equivalents | September 30, 2025 | $42.63M | +4.3% | +105.1% |
| Stockholders Equity | September 30, 2025 | $180.47M | -14.2% | +5.3% |
| R&D Expense | September 30, 2025 | $10.99M | +13.0% | -21.8% |
| Operating Income | September 30, 2025 | -$14.93M | -15.1% | +16.6% |
| Shares Outstanding | March 31, 2024 | 2.38M | — | +1.5% |
- Contineum Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2024.
- Contineum Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2024.
- Contineum Therapeutics, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported Net Income of -$59.98 million for fiscal year 2025.
- Contineum Therapeutics, Inc. showed a decrease of -41.9% in Net Income compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported Diluted EPS of $2.17 per share (loss) for fiscal year 2025.
- Contineum Therapeutics, Inc. showed an increase of +0.5% in Diluted EPS compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported Total Assets of $276.64 million for fiscal year 2025.
- Contineum Therapeutics, Inc. showed an increase of +30.0% in Total Assets compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported Cash and Equivalents of $75.60 million for fiscal year 2025.
- Contineum Therapeutics, Inc. showed an increase of +244.5% in Cash and Equivalents compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported Stockholders Equity of $260.99 million for fiscal year 2025.
- Contineum Therapeutics, Inc. showed an increase of +31.8% in Stockholders Equity compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported R&D Expense of $51.52 million for fiscal year 2025.
- Contineum Therapeutics, Inc. showed an increase of +34.1% in R&D Expense compared to the prior fiscal year.
- Contineum Therapeutics, Inc. reported Operating Income of -$68.06 million for fiscal year 2025.
- Contineum Therapeutics, Inc. showed a decrease of -33.7% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: